Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis. // Surgical Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0960740426002513?dgcid=rss_sd_all
Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis. Surgical Oncology. https://www.sciencedirect.com/science/article/pii/S0960740426002513?dgcid=rss_sd_all
“Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis.” Surgical Oncology.
@article{article67010,
title = {Lenvatinib vs sorafenib as second-line therapy after ATE+BEV failure in advanced hepatocellular carcinoma: A meta-analysis},
journal = {Surgical Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0960740426002513?dgcid=rss_sd_all}
}
ABSTRACT Objectives The aim of this study was to determine whether certain cephalometric findings can predict the future need for orthognathic surgery (OS) in cleft lip (CL), cleft palate (CP), unilateral cleft lip and palate (UCLP),...